iTonic Holdings Ltd ITOC
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.32
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $523.0K | $448.2K | $628.6K | $679.8K | — |
| Cost of revenue | $195.7K | $67.0K | $157.8K | $121.6K | — |
| Gross profit | $327.4K | $381.2K | $470.8K | $558.1K | — |
| R&D | $459.1K | $93.3K | $84.5K | $73.7K | — |
| SG&A | $4.9M | $750.6K | $424.9K | $162.1K | — |
| Total operating expenses | $5.5M | $1.2M | $777.5K | $530.6K | — |
| Operating income | -$5.2M | -$770.3K | -$306.7K | $27.5K | — |
| Pre-tax income | -$5.1M | -$638.8K | -$260.5K | $71.0K | — |
| Income tax | — | $21.8K | $19.3K | $13.0K | — |
| Net income | -$5.1M | -$660.6K | -$241.2K | $84.0K | — |
| EPS, basic | -0.32 | -0.05 | -0.02 | 0.01 | — |
| EPS, diluted | -0.32 | -0.05 | -0.02 | 0.01 | — |
| Shares, diluted (wtd. avg.) | 16.0M | 12.7M | 12.0M | 12.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $1.5M | $6.2M | $217.9K | $72.3K | $136.8K |
| Short-term investments | $1.4M | — | — | — | — |
| Receivables | $288.5K | $281.6K | $206.3K | — | — |
| Inventory | $52.5K | $117.4K | $52.3K | — | — |
| Total current assets | $4.1M | $6.7M | $532.5K | — | — |
| Property, plant and equipment | $37.8K | $45.6K | $58.9K | — | — |
| Goodwill | $2.0M | — | — | — | — |
| Other intangibles | $2.4M | — | — | — | — |
| Total assets | $9.1M | $6.7M | $1.6M | — | — |
| Accounts payable | $66.9K | $10.4K | $18.0K | — | — |
| Total current liabilities | $462.8K | $538.6K | $1.2M | — | — |
| Total liabilities | $969.8K | $538.6K | $1.3M | — | — |
| Retained earnings | -$5.6M | -$522.9K | $137.7K | — | — |
| Total equity | $6.1M | $6.2M | $306.3K | $556.3K | $954.3K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$3.2M | -$775.0K | -$63.6K | -$116.2K | — |
| Stock-based compensation | $2.9M | — | — | — | — |
| Capital expenditure | $3.8K | $861 | — | — | — |
| Investing cash flow | -$1.4M | -$861 | — | — | — |
| Financing cash flow | -$91.6K | $6.7M | $220.6K | $78.1K | — |
| Dividends paid | $8.9K | — | — | $398.4K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-039356.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $679.8K | $628.6K | $448.2K | $523.0K |
| Gross profit | — | $558.1K | $470.8K | $381.2K | $327.4K |
| Net income | — | $84.0K | -$241.2K | -$660.6K | -$5.1M |
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $122.04B | 25.6x | 8.4% |
| LIVN | LivaNova PLC | $4.46B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $2.45B | 14.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.05B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.89B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.6x | 5.2% |
| CBLL | Ceribell, Inc. | $1.04B | — | 36.1% |